PTC CLINIC
Informace pro odborníky

Reference, klinické a dozimetrické studie thymom a thymický karcinom

1. NCCN guildelines Thymomas and Thymic Carcinomas, Version 2.2025
2. ASTRO Model Policies , Proton Beam Therapy Model Policy
3. Rimner A, Yao X, Huang J, Antonicelli A, Ahmad U, Korst RJ, Detterbeck F, Gomez DR. Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma-An Analysis of the International Thymic Malignancies Interest Group Retrospective Database. J Thorac Oncol. 2016 Oct;11(10):1785-92. Journal of Thoracic Oncology, Volume 11, Issue 10, 1785 – 1792
4. Shepherd A, Riely G, Detterbeck F, Simone CB 2nd, Ahmad U, Huang J, Korst R, Rajan A, Rimner A. Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. J Thorac Oncol. 2017 Apr;12(4):745-751.
5. Chun SG, Rimner A, Amini A, Chang JY, Donington J, Edelman MJ, Geng Y, Gubens MA, Higgins KA, Iyengar P, Movsas B, Ning MS, Park HS, Rodrigues G, Wolf A, Simone CB 2nd. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncol. 2023 Jul 1;9(7):971-980.

6. Vogel J., Berman A.T., Lin L. et al. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma. Radiother Oncol., 2016;118(3):504–509. DOI: 10.1016/j.radonc.2016.02.003

7. Parikh R.R., Rhome R., Hug E. et al. Adjuvant proton beam therapy in the management of thymoma: a dosimetric comparison and acute toxicities. Clin Lung Cancer, 2016;17(5):362–366. DOI: 10.1016/j.cllc.2016.05.019

8. Mercado C.E., Hartsell W.F., Simone C.B. et al. Proton therapy for thymic malignancies: multi‑institutional patterns‑of‑care and early clinical outcomes from the Proton Collaborative Group and University of Florida prospective registries. Acta Oncol., 2019;58(7):1036–1040. DOI: 10.1080/0284186X.2019.1575981

9. Vogel J., Lin L., Litzky L.A., Berman A.T., Simone C.B. 2nd. Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma. Int J Radiat Oncol Biol Phys., 2017;99(2):427–433. DOI: 10.1016/j.ijrobp.2017.04.022

10. Gomez D., Komaki R. State of the art in radiation therapy for thymic malignancies. J Thorac Oncol., 2010;5(10 Suppl 4):S336–343. DOI: 10.1097/JTO.0b013e3181f20ea2

11. Girard N., Mornex F. The role of radiotherapy in the management of thymic tumors. Thorac Surg Clin., 2011;21(1):99–105. DOI: 10.1016/j.thorsurg.2010.08.011

12. Zhu H.J., Hoppe B.S., Flampouri S. et al. Rationale and early outcomes for the management of thymoma with proton therapy. Transl Lung Cancer Res., 2018;7(1):106–113. DOI: 10.21037/tlcr.2018.01.06

13. Haefner M.F., Verma V., Bougatf N. et al. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta Oncol., 2018;57(12):1713–1720. DOI: 10.1080/0284186X.2018.1519995

14. Loap P., Scher N., Goudjil F., Kirova Y., Girard N., Cao K.I. Proton beam therapy for thymic carcinoma with pericardial involvement. Int J Particle Ther., 2021;7(3):65–70. DOI: 10.14338/IJPT‑20‑00023.1

15. Tomita N., Okuda K., Ogawa Y. et al. Relationship between radiation doses to heart substructures and radiation pneumonitis in patients with thymic epithelial tumors. Sci Rep., 2020;10:11191. DOI: 10.1038/s41598-020-67935-8